Two independent multicenter efforts reported that genomic profiling can identify melanoma patients at very low risk of lymph‑node metastasis and could reduce the need for sentinel lymph node biopsy. A Moffitt-led gene expression profile and a Mayo Clinic–SkylineDx collaboration published in JAMA Surgery described algorithms that integrate molecular signals with clinicopathologic features to stratify node‑positive risk. If prospectively validated, the tests could change surgical decision making and lower procedure rates.